Oncovin

DRUG3 trials

Sponsors

The Lymphoma Academic Research Organisation, Hoffmann-La Roche, University of Colorado, Denver

Conditions

Hodgkin LymphomaLymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell LymphomaPeripheral T Cell Lymphoma

Phase 1

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

CompletedNCT03586999

University of Colorado, DenverPeripheral T Cell Lymphoma

Start: 2018-11-07End: 2022-09-20Updated: 2024-10-29

Phase 2

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD

CompletedNCT02298283

The Lymphoma Academic Research OrganisationHodgkin Lymphoma

Start: 2015-04-30End: 2020-07-09Updated: 2021-07-26

Unknown Phase

MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma

CompletedNCT02486952

Hoffmann-La RocheLymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Start: 2005-08-31End: 2011-01-31Updated: 2016-02-22

Related Papers

BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDY

Hematological Oncology2021-06-01